新型多巴胺激动剂普拉克索可改善帕金森病的帕金森症状及抑郁症状。

New dopamine agonist pramipexole improves parkinsonism and depression in Parkinson's disease.

作者信息

Harada Toshihide, Ishizaki Fumiko, Horie Nobuko, Nitta Yumiko, Yamada Tohru, Sasaki Tomohiro, Nagakane Tomoomi, Yasumatsu Yoshiteru, Nitta Kohsaku, Katsuoka Hiroyuki

机构信息

Faculty of Health and Welfare, Prefectural University of Hiroshima, 1-1, Gakuen-machi, Mihara, Hiroshima 723-0053, Japan.

出版信息

Hiroshima J Med Sci. 2011 Dec;60(4):79-82.

PMID:22389951

Abstract

Previous studies have shown that pramipexole might have the potential to improve depressive symptoms in patients with Parkinson's disease. To provide more evidence, in five Japanese patients at Hoehn & Yahr stage 1-3 we evaluated the Unified Parkinson's Disease Rating Scale (UPDRS), Hamilton Depression Rating Scale (HAMD) and Montgomery Asberg Depression Rating Scale (MADRS) at our hospital. After the pramipexole treatment, each total score of UPDRS, HAMD and MADRS significantly decreased compared with that before the treatment. Our data indicate that pramipexole improves depressive symptoms in patients with Parkinson's disease.

摘要

先前的研究表明，普拉克索可能具有改善帕金森病患者抑郁症状的潜力。为了提供更多证据，我们在本院对5例处于Hoehn & Yahr 1-3期的日本患者进行了评估，采用统一帕金森病评定量表（UPDRS）、汉密尔顿抑郁评定量表（HAMD）和蒙哥马利-艾斯伯格抑郁评定量表（MADRS）。普拉克索治疗后，UPDRS、HAMD和MADRS的各项总分与治疗前相比均显著降低。我们的数据表明，普拉克索可改善帕金森病患者的抑郁症状。